



**Now
Enrolling**



Company: Traveře Therapeutics

Total time in study: About 9 months

Goal: To learn more about classical homocystinuria (HCU),
and how safe and effective pegtibatınase may be in patients with HCU

Phase: This is a Phase 3 study that follows a Phase 1/Phase 2 study called COMPOSE

Who can take part?

- ✓ People with a diagnosis of HCU
 - ✓ People 12 to 65 years of age
- Other factors and restrictions
also apply*

What is the study drug?

- ✓ Participants will receive
pegtibatınase or placebo
(an inactive medication)

Why participate in the study?

- ✓ You may help others with HCU
- ✓ You will help contribute to new research
and further understanding of HCU
- ✓ You will receive additional monitoring
and testing



Study locations include:
United States, Europe,
the Middle East, Asia
Pacific, and South
America.



About 70 people
with HCU will
take part in
the study.



Payment for time and
travel may be available
to participants and their
caregivers.

Periods during the study



SCREENING PERIOD

To check if
the right
study is
for you



PRE-TREATMENT PERIOD

To understand
your current diet
and how to keep
it stable during
the study



STUDY TREATMENT PERIOD

To receive pegtibatınase
or the placebo



FOLLOW-UP PERIOD

To check your
health after
the Study
Treatment
Period

After completing the **HARMONY Study**, it may be possible for participants to join a long-term follow-on study and continue or start receiving pegtibatınase.

To find out more, please contact:
MedInfo@traverse.com



For more information, please
scan the QR code or visit:
www.hcuconnection.com